Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.
Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.
Abstract: Described are topical, transdermal and transmucosal pharmaceutical compositions comprising bremelanotide that include bremelanotide or a pharmaceutically acceptable salt thereof and a permeation enhancer, in any form suitable for topical, transdermal or transmucosal delivery, including transmucosal delivery through the gastrointestinal tract after oral administration. Also provided are methods of making and using the pharmaceutical compositions.
Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
Abstract: Described are compositions, methods and devices for providing sustained transdermal drug delivery using anti-healing compounds to prolong the effects of active transdermal technologies.
Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of norethindrone acetate in the form of a flexible finite system for topical application, comprising a drug-in-adhesive polymer matrix comprising norethindrone acetate (NETA) as the only systemically active drug, an adhesive polymer selected from silicone adhesives and polyisobutylene (PIB) adhesives, a penetration enhancer, and a crystallization inhibitor. Methods of making and using the systems also are described.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
Abstract: Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described.
Abstract: Described are methods for oral administration of therapeutic proteins and peptides, more specifically to the oral administration of therapeutic proteins and peptides with gastric acid modulators, and compositions of comprising a gastric acid modulator and a protein or peptide.
Type:
Application
Filed:
December 29, 2016
Publication date:
July 6, 2017
Applicant:
NOVEN PHARMACEUTICALS, INC.
Inventors:
Jeffrey Klein, Anubhav Arora, Puchun Liu
Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.
Abstract: Described are transdermal drug delivery systems for extended delivery of a therapeutic agent in the form of a flexible finite system for topical application, comprising (i) a polymer matrix comprising a therapeutic agent and (ii) a face adhesive layer disposed on a skin-contacting side of the polymer matrix comprising a rubber-based polymer. Methods of making and using such systems also are described.
Abstract: Described are transdermal pharmaceutical compositions exhibiting reduced skin irritation potential comprising a steroid and an antioxidant, useful for reducing the skin irritation associated with the use of transdermal drug delivery compositions. Methods of making and using the compositions also are described.
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Abstract: Multi-polymer compositions for the transdermal delivery of drugs, such as amine-functional drugs, in a flexible, finite form are described. The compositions comprise a polymer matrix that includes a drug or a pharmaceutically acceptable salt thereof and a polymer matrix comprising acrylic polymer(s), polyisobutylene polymer(s) and styrene-isoprene-styrene block copolymer(s). Methods of manufacturing and methods of using the compositions also are described.